Global Medical Marijuana Market - 2025 -2033
Medical Marijuana Market Overview
The medical marijuana market is estimated to reach at a high CAGR of 17.71 % during the forecast period (2024-2031).
To treat diseases the marijuana plant or chemicals present in it is used as medical marijuana. It's the same product as marijuana, but it's taken for medical purposes. More than 100 different chemicals called cannabinoids are present in marijuana plant.
Market Dynamics
The increasing prevalence of conditions that require medical marijuana for treatment and the legalization of marijuana in developing countries is expected to rise the market of medical marijuana.
The increasing prevalence of conditions that require medical marijuana for the treatment
For decades the potential medicinal properties of marijuana and its components have been the subject of research and heated debate. Tetrahydrocannabinol itself has proven medical benefits in particular formulations. For the treatment of nausea and vomiting in patients undergoing chemotherapy for cancer and to stimulate appetite in patients with wasting syndrome due to AIDS, the U.S. FDA has approved THC-based medications nabilone (Cesamet®)and dronabinol (Marinol®) prescribed in pill form. Several other marijuana-based medications have been approved or are undergoing clinical trials. A mouth spray Nabiximols (Sativex®) for treating the spasticity and neuropathic pain that may accompany multiple sclerosis combines with tetrahydrocannabinol another chemical found in marijuana called cannabidiol (CBD) is currently available in the U.K, Canada, and several European countries.
The FDA has also approved Epidiolex a CBD-based liquid medication for the treatment of two forms of severe childhood epilepsy,Lennox-Gastaut syndrome and Dravet syndrome. It’s delivered to patients in a reliable dosage form and through a reproducible delivery route to ensure that patients derive the anticipated benefits.
A few clinical trials have found that cannabis can help manage behavioral symptoms in people with dementia, including aggression and agitation, but only in some cases. The Alzheimer Society Research Program has funded research on how endocannabinoids affect mood and anxiety in dementia and how the synthetic cannabinoid nabilone can treat agitation in alzheimer’s disease.
The legalization of marijuana in developing countries is expected to drive the demand for medical marijuana
Marijuana at the federal level is still illegal as a Schedule I drug under the federal Controlled Substances Act. However, states continue to legalize marijuana through ballot initiatives and legislation. In 2021, 4 states (New York ,New Mexico, Virginia and Connecticut) passed legislation to legalize marijuana for recreational purposes. The District of Columbia and 19 states have legalized the recreational use of marijuana. As of May 18 2021, 36 states and four territories allow for the medical use of cannabis products.
Tetrahydrocannabinolis (THC) the psychoactive compound in marijuana is responsible for the 'high' people feel. There are two man-made drugs called nabilone (Cesamet) and dronabinol (Marinol) synthetic forms of THC. They are FDA-approved to prevent vomiting and nausea in people undergoing chemotherapy
Stringent FDA rules and other regulations are some of the factors that will hamper the medical marijuana market
For the treatment of any condition or disease, the agency has not approved a marketing application for cannabis. FDA has approved three cannabis-related and one cannabis-derived drug products. These products will only be available with a prescription from a licensed healthcare provider.Epidiolex FDA approved drug contains a purified form of the drug substance CBD to treat seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in patients one year of age and older. This means FDA has concluded that this particular drug product is effective and safe for its intended use.
To protect public health the agency has, will continue to monitor the marketplace and take action as needed against companies illegally selling cannabis and cannabis-derived products that can put consumers at risk and marketed for therapeutic uses for which they are not approved. FDA recognizes the potential therapeutic opportunities that cannabis-derived or cannabis compounds could offer and acknowledge the significant interest in these possibilities. FDA believes that the process of drug approval represents the best way to help ensure safe and effective new medicines, including any drugs derived from cannabis, are available to patients in need of appropriate medical therapy. The Center for Drug Evaluation and Research (CDER) is committed to supporting the development of new drugs, including cannabis and cannabis-derived drugs, through the investigational new drug (IND) and drug approval process.
COVID-19 Impact Analysis On Medical Marijuana Market
COVID-19 has affected the healthcare industry. To curb its growth, government-imposed lockdown. People are fearful they will experience occupational effects and negative health from the COVID-19 pandemic. This has seen to affect the medical marijuana market as many have stopped manufacturing units.
Market Segment Analysis
The extract Form segment will dominate the medical marijuana market
One of the most popular way of consumption of medical marijuana is by vaporizing the flower (dry-leaf) of the marijuana plant. The plant is heated to extract the cannabinoids and are left with a resulting vapor that is inhaled.Extract of cannabis is a specific type of cannabis concentrate. While concentrates can be made through the use of a solvent and different mechanical processes, extracts are unique because they are made exclusively through a solvent.
Extracts are concentrated forms of marijuana that are isolated by heating the plant’s oily components. They can be inhaled or vaporized and come in a variety of forms. Some common forms of extracts are shatter (smooth, solid, transparent, and higher in THC), wax (opaque, soft, and lower in THC), oil (sticky, liquid, and varying in THC), budder (creamy, butter-like, and higher in THC), and resin (dark, gooey, and higher in THC). These are usually available to be consumed in a vaporizer cartridge or by themselves to be vaporized.
Pain Management will dominate the medical marijuana market
Chronic pain affects more people than diabetes, heart disease and cancer combined. Marijuana contains compounds that may relieve pain, nausea, and other symptoms. Most studies focus on the components of marijuana for pain relief are cannabidiol (CBD) and tetrahydrocannabinol (THC). Tetrahydrocannabinol resembles the cannabinoid chemicals that occur naturally in the body. Inhalation or ingestion of tetrahydrocannabinol by people, stimulates the brain’s cannabinoid receptors. This reduces pain levels and activates the brain’s reward system. Tetrahydrocannabinol is a psychoactive compound as it binds to cannabinoid receptors and produces an elevated state of mind, known as a high. CBD does not cause a high, although it does interact with pain receptors in the brain to exert pain-relieving and anti-inflammatory effects.
Of about 17,000 people with cancer, 70 percent reportedly experienced general well-being and improved pain after use of marijuana. After using the drug people with chronic migraines experienced a decrease in migraine episodes.
The retail Pharmacy segment dominated the medical marijuana market
Due to the US DEA classification of marijuana as a Schedule, I drug, meaning there is a high potential for abuse and no medical use, healthcare providers have not been adequately educated about its use. No clinical guidelines exist to guide dosing or indications for use, making it difficult to have a standardized treatment approach, especially with differing state regulations. Instead of traditional pharmacies, patients seeking marijuana for medicinal use often go to dispensaries. Some dispensaries focus on stocking and selling only recreational products or medicinal products, while others offer both.
A retail pharmacy would be the safest place for dispensing medical marijuana. Pharmacists are experts in medication and play a significant role in dispensing and monitoring medication to ensure safe and optimal use. Dispensing medical marijuana like other medications through pharmacy is the safest option.
Market Geographical Share
North America region will dominate the medical marijuana market
In the United States, cannabis for medical purposes is legal in 36 states, four out of five permanently inhabited U.S. territories, and the District of Columbia, as of May 2021. It's the world's most commonly used, trafficked and cultivated drug. Despite the plant being illegal under federal law as a Schedule I drug. According to New Frontier Data in 2019 the U.S. legal marijuana industry was estimated at $13.6 billion with 340,000 jobs devoted to the handling of plants,
The District of Columbia and a total of 35 states have marijuana legalized for medical use, as of April 2021 16 of which allow adults to legally use the drug for recreational use. The number may continue to rise, as more people are accepting the idea of legalizing marijuana across the United States.
Market Companies
Major key players in the Medical Marijuana Market are Aphria Incorporation GW Pharmaceuticals PLC, MedReleaf Corporation, Aurora Cannabis Inc, Medical Marijuana, Inc., Insys Therapeutics, Inc., The Peace Naturals Project, Cannabis Sativa, INC., Green Relief Inc.,Institute Of Materia Medica, Canopy Growth Corporation and Chinese Academy Of Agricultural Sciences
Medical Marijuana Market Key Companies to Watch
GW Pharmaceuticals PLC
Overview: GW Pharmaceuticals (GW), and U.S. subsidiary Greenwich Biosciences, is a global biopharmaceutical company that has established a world-leading cannabinoid science and medicines position. Founded over two decades ago in response to significant unmet patient needs, patients remain their key focus, improve their motivation and quality of life. GW’s pioneering work has led to the regulatory approval of world-first, potentially life-changing, cannabis-based medicines in 42 countries worldwide. Their continued dedication has resulted in the treatment of thousands of patients with medicines, including more than 8,000 as part of their clinical trials programs.
Product Portfolio: GW has established a world-leading position in the development of plant-derived cannabinoid therapeutics through its proven development processes and drug discovery, intellectual property portfolio and regulatory and manufacturing expertise. The company has a pipeline of additional clinical-stage cannabinoid product candidates under development for both orphan and non-orphan indications, focusing on neurological conditions.
Key Development: On May 05, 2021, Jazz Pharmaceuticals has announced the completion of its acquisition of GW Pharmaceuticals plc, a leader in the development, science and commercialization of cannabinoid-based prescription medicines.
The Medical Marijuana Market report would provide an access to an approx. 60 market data table, 48 figures and 200 pages.
The medical marijuana market is estimated to reach at a high CAGR of 17.71 % during the forecast period (2024-2031).
To treat diseases the marijuana plant or chemicals present in it is used as medical marijuana. It's the same product as marijuana, but it's taken for medical purposes. More than 100 different chemicals called cannabinoids are present in marijuana plant.
Market Dynamics
The increasing prevalence of conditions that require medical marijuana for treatment and the legalization of marijuana in developing countries is expected to rise the market of medical marijuana.
The increasing prevalence of conditions that require medical marijuana for the treatment
For decades the potential medicinal properties of marijuana and its components have been the subject of research and heated debate. Tetrahydrocannabinol itself has proven medical benefits in particular formulations. For the treatment of nausea and vomiting in patients undergoing chemotherapy for cancer and to stimulate appetite in patients with wasting syndrome due to AIDS, the U.S. FDA has approved THC-based medications nabilone (Cesamet®)and dronabinol (Marinol®) prescribed in pill form. Several other marijuana-based medications have been approved or are undergoing clinical trials. A mouth spray Nabiximols (Sativex®) for treating the spasticity and neuropathic pain that may accompany multiple sclerosis combines with tetrahydrocannabinol another chemical found in marijuana called cannabidiol (CBD) is currently available in the U.K, Canada, and several European countries.
The FDA has also approved Epidiolex a CBD-based liquid medication for the treatment of two forms of severe childhood epilepsy,Lennox-Gastaut syndrome and Dravet syndrome. It’s delivered to patients in a reliable dosage form and through a reproducible delivery route to ensure that patients derive the anticipated benefits.
A few clinical trials have found that cannabis can help manage behavioral symptoms in people with dementia, including aggression and agitation, but only in some cases. The Alzheimer Society Research Program has funded research on how endocannabinoids affect mood and anxiety in dementia and how the synthetic cannabinoid nabilone can treat agitation in alzheimer’s disease.
The legalization of marijuana in developing countries is expected to drive the demand for medical marijuana
Marijuana at the federal level is still illegal as a Schedule I drug under the federal Controlled Substances Act. However, states continue to legalize marijuana through ballot initiatives and legislation. In 2021, 4 states (New York ,New Mexico, Virginia and Connecticut) passed legislation to legalize marijuana for recreational purposes. The District of Columbia and 19 states have legalized the recreational use of marijuana. As of May 18 2021, 36 states and four territories allow for the medical use of cannabis products.
Tetrahydrocannabinolis (THC) the psychoactive compound in marijuana is responsible for the 'high' people feel. There are two man-made drugs called nabilone (Cesamet) and dronabinol (Marinol) synthetic forms of THC. They are FDA-approved to prevent vomiting and nausea in people undergoing chemotherapy
Stringent FDA rules and other regulations are some of the factors that will hamper the medical marijuana market
For the treatment of any condition or disease, the agency has not approved a marketing application for cannabis. FDA has approved three cannabis-related and one cannabis-derived drug products. These products will only be available with a prescription from a licensed healthcare provider.Epidiolex FDA approved drug contains a purified form of the drug substance CBD to treat seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in patients one year of age and older. This means FDA has concluded that this particular drug product is effective and safe for its intended use.
To protect public health the agency has, will continue to monitor the marketplace and take action as needed against companies illegally selling cannabis and cannabis-derived products that can put consumers at risk and marketed for therapeutic uses for which they are not approved. FDA recognizes the potential therapeutic opportunities that cannabis-derived or cannabis compounds could offer and acknowledge the significant interest in these possibilities. FDA believes that the process of drug approval represents the best way to help ensure safe and effective new medicines, including any drugs derived from cannabis, are available to patients in need of appropriate medical therapy. The Center for Drug Evaluation and Research (CDER) is committed to supporting the development of new drugs, including cannabis and cannabis-derived drugs, through the investigational new drug (IND) and drug approval process.
COVID-19 Impact Analysis On Medical Marijuana Market
COVID-19 has affected the healthcare industry. To curb its growth, government-imposed lockdown. People are fearful they will experience occupational effects and negative health from the COVID-19 pandemic. This has seen to affect the medical marijuana market as many have stopped manufacturing units.
Market Segment Analysis
The extract Form segment will dominate the medical marijuana market
One of the most popular way of consumption of medical marijuana is by vaporizing the flower (dry-leaf) of the marijuana plant. The plant is heated to extract the cannabinoids and are left with a resulting vapor that is inhaled.Extract of cannabis is a specific type of cannabis concentrate. While concentrates can be made through the use of a solvent and different mechanical processes, extracts are unique because they are made exclusively through a solvent.
Extracts are concentrated forms of marijuana that are isolated by heating the plant’s oily components. They can be inhaled or vaporized and come in a variety of forms. Some common forms of extracts are shatter (smooth, solid, transparent, and higher in THC), wax (opaque, soft, and lower in THC), oil (sticky, liquid, and varying in THC), budder (creamy, butter-like, and higher in THC), and resin (dark, gooey, and higher in THC). These are usually available to be consumed in a vaporizer cartridge or by themselves to be vaporized.
Pain Management will dominate the medical marijuana market
Chronic pain affects more people than diabetes, heart disease and cancer combined. Marijuana contains compounds that may relieve pain, nausea, and other symptoms. Most studies focus on the components of marijuana for pain relief are cannabidiol (CBD) and tetrahydrocannabinol (THC). Tetrahydrocannabinol resembles the cannabinoid chemicals that occur naturally in the body. Inhalation or ingestion of tetrahydrocannabinol by people, stimulates the brain’s cannabinoid receptors. This reduces pain levels and activates the brain’s reward system. Tetrahydrocannabinol is a psychoactive compound as it binds to cannabinoid receptors and produces an elevated state of mind, known as a high. CBD does not cause a high, although it does interact with pain receptors in the brain to exert pain-relieving and anti-inflammatory effects.
Of about 17,000 people with cancer, 70 percent reportedly experienced general well-being and improved pain after use of marijuana. After using the drug people with chronic migraines experienced a decrease in migraine episodes.
The retail Pharmacy segment dominated the medical marijuana market
Due to the US DEA classification of marijuana as a Schedule, I drug, meaning there is a high potential for abuse and no medical use, healthcare providers have not been adequately educated about its use. No clinical guidelines exist to guide dosing or indications for use, making it difficult to have a standardized treatment approach, especially with differing state regulations. Instead of traditional pharmacies, patients seeking marijuana for medicinal use often go to dispensaries. Some dispensaries focus on stocking and selling only recreational products or medicinal products, while others offer both.
A retail pharmacy would be the safest place for dispensing medical marijuana. Pharmacists are experts in medication and play a significant role in dispensing and monitoring medication to ensure safe and optimal use. Dispensing medical marijuana like other medications through pharmacy is the safest option.
Market Geographical Share
North America region will dominate the medical marijuana market
In the United States, cannabis for medical purposes is legal in 36 states, four out of five permanently inhabited U.S. territories, and the District of Columbia, as of May 2021. It's the world's most commonly used, trafficked and cultivated drug. Despite the plant being illegal under federal law as a Schedule I drug. According to New Frontier Data in 2019 the U.S. legal marijuana industry was estimated at $13.6 billion with 340,000 jobs devoted to the handling of plants,
The District of Columbia and a total of 35 states have marijuana legalized for medical use, as of April 2021 16 of which allow adults to legally use the drug for recreational use. The number may continue to rise, as more people are accepting the idea of legalizing marijuana across the United States.
Market Companies
Major key players in the Medical Marijuana Market are Aphria Incorporation GW Pharmaceuticals PLC, MedReleaf Corporation, Aurora Cannabis Inc, Medical Marijuana, Inc., Insys Therapeutics, Inc., The Peace Naturals Project, Cannabis Sativa, INC., Green Relief Inc.,Institute Of Materia Medica, Canopy Growth Corporation and Chinese Academy Of Agricultural Sciences
Medical Marijuana Market Key Companies to Watch
GW Pharmaceuticals PLC
Overview: GW Pharmaceuticals (GW), and U.S. subsidiary Greenwich Biosciences, is a global biopharmaceutical company that has established a world-leading cannabinoid science and medicines position. Founded over two decades ago in response to significant unmet patient needs, patients remain their key focus, improve their motivation and quality of life. GW’s pioneering work has led to the regulatory approval of world-first, potentially life-changing, cannabis-based medicines in 42 countries worldwide. Their continued dedication has resulted in the treatment of thousands of patients with medicines, including more than 8,000 as part of their clinical trials programs.
Product Portfolio: GW has established a world-leading position in the development of plant-derived cannabinoid therapeutics through its proven development processes and drug discovery, intellectual property portfolio and regulatory and manufacturing expertise. The company has a pipeline of additional clinical-stage cannabinoid product candidates under development for both orphan and non-orphan indications, focusing on neurological conditions.
Key Development: On May 05, 2021, Jazz Pharmaceuticals has announced the completion of its acquisition of GW Pharmaceuticals plc, a leader in the development, science and commercialization of cannabinoid-based prescription medicines.
The Medical Marijuana Market report would provide an access to an approx. 60 market data table, 48 figures and 200 pages.
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Market Snippet By Product Type
3.2. Market Snippet By Application
3.3. Market Snippet By Distribution Channel
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of conditions that require medical marijuana for the treatment
4.1.1.2. The legalization of marijuana in developing countries is expected to drive the demand for medical marijuana
4.1.2. Restraints:
4.1.2.1. Stringent FDA and other regulations are some of the factors that will hamper the medical marijuana market
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Epidemiology Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Regulatory Analysis
5.6. Reimbursement Analysis
5.7. Unmet Needs
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY PRODUCT TYPE
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
7.1.2. Market Attractiveness Index, By Product Type Segment
7.2. Extract Form*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2018-2029 and Y-o-Y Growth Analysis (%), 2020-2029
7.3. Dried Form
8. BY APPLICATION
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Pain management*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2018-2029 and Y-o-Y Growth Analysis (%), 2020-2029
8.3. Seizures
9. BY DISTRIBUTION CHANNEL
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
9.1.2. Market Attractiveness Index, By Distribution Channel Segment
9.2. Retail Pharmacy *
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2018-2029 and Y-o-Y Growth Analysis (%), 2020-2029
9.3. E-Commerce
10. BY REGION
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2018-2029 and Y-o-Y Growth Analysis (%), 2020-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11. COMPETITIVE LANDSCAPE
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking
11.4. List of Key Companies to Watch
11.5. List of Company with disruptive technology
11.6. List of Start Up Companies
12. COMPANY PROFILES
12.1. GW Pharmaceuticals PLC*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. MedReleaf Corporation
12.3. Canopy Growth Corporation
12.4. Aphria Incorporation
12.5. Aurora Cannabis Inc
12.6. Medical Marijuana, Inc.
12.7. Green Relief Inc.
12.8. Chinese Academy Of Agricultural Sciences
12.9. Chongqing Fujin Biology Medical Company
12.10. Wanbang Medical Company(*LIST NOT EXHAUSTIVE)
13. DATAM INTELLIGENCE
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Market Snippet By Product Type
3.2. Market Snippet By Application
3.3. Market Snippet By Distribution Channel
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of conditions that require medical marijuana for the treatment
4.1.1.2. The legalization of marijuana in developing countries is expected to drive the demand for medical marijuana
4.1.2. Restraints:
4.1.2.1. Stringent FDA and other regulations are some of the factors that will hamper the medical marijuana market
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Epidemiology Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Regulatory Analysis
5.6. Reimbursement Analysis
5.7. Unmet Needs
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY PRODUCT TYPE
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
7.1.2. Market Attractiveness Index, By Product Type Segment
7.2. Extract Form*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2018-2029 and Y-o-Y Growth Analysis (%), 2020-2029
7.3. Dried Form
8. BY APPLICATION
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Pain management*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2018-2029 and Y-o-Y Growth Analysis (%), 2020-2029
8.3. Seizures
9. BY DISTRIBUTION CHANNEL
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
9.1.2. Market Attractiveness Index, By Distribution Channel Segment
9.2. Retail Pharmacy *
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2018-2029 and Y-o-Y Growth Analysis (%), 2020-2029
9.3. E-Commerce
10. BY REGION
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2018-2029 and Y-o-Y Growth Analysis (%), 2020-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11. COMPETITIVE LANDSCAPE
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking
11.4. List of Key Companies to Watch
11.5. List of Company with disruptive technology
11.6. List of Start Up Companies
12. COMPANY PROFILES
12.1. GW Pharmaceuticals PLC*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. MedReleaf Corporation
12.3. Canopy Growth Corporation
12.4. Aphria Incorporation
12.5. Aurora Cannabis Inc
12.6. Medical Marijuana, Inc.
12.7. Green Relief Inc.
12.8. Chinese Academy Of Agricultural Sciences
12.9. Chongqing Fujin Biology Medical Company
12.10. Wanbang Medical Company(*LIST NOT EXHAUSTIVE)
13. DATAM INTELLIGENCE
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us
LIST OF TABLES
Table 01 Medical Marijuana Market Value, By Product Type, 2021, 2025 & 2029($ Million)
Table 02 Medical Marijuana Market Value, By Application, 2021, 2025 & 2029($ Million)
Table 03 Medical Marijuana Market Value, By Distribution Channel, 2021, 2025 & 2029($ Million)
Table 04 Medical Marijuana Market Value, By Product Type, 2021, 2025 & 2029($ Million)
Table 05 Medical Marijuana Market Value, By Product Type, 2018-2029 ($ Million)
Table 06 Medical Marijuana Market Value, By Application, 2021, 2025 & 2029($ Million)
Table 07 Medical Marijuana Market Value, By Application, 2018-2029 ($ Million)
Table 08 Medical Marijuana Market Value, By Distribution Channel, 2021, 2025 & 2029($ Million)
Table 09 Medical Marijuana Market Value, By Distribution Channel, 2018-2029 ($ Million)
Table 10 Medical Marijuana Market Value, By Region, 2021, 2025 & 2029($ Million)
Table 11 Medical Marijuana Market Value, By Region, 2018-2029 ($ Million)
Table 12 North America Medical Marijuana Market Value, By Product Type, 2018-2029 ($ Million)
Table 13 North America Medical Marijuana Market Value, By Application, 2018-2029 ($ Million)
Table 14 North America Medical Marijuana Market Value, By Distribution Channel, 2018-2029 ($ Million)
Table 15 North America Medical Marijuana Market Value, By Country, 2018-2029 ($ Million)
Table 16 South America Medical Marijuana Market Value, By Product Type, 2018-2029 ($ Million)
Table 17 South America Medical Marijuana Market Value, By Application, 2018-2029 ($ Million)
Table 18 South America Medical Marijuana Market Value, By Distribution Channel, 2018-2029 ($ Million)
Table 19 South America Medical Marijuana Market Value, By Country, 2018-2029 ($ Million)
Table 20 Europe Medical Marijuana Market Value, By Product Type, 2018-2029 ($ Million)
Table 21 Europe Medical Marijuana Market Value, By Application, 2018-2029 ($ Million)
Table 22 Europe Medical Marijuana Market Value, By Distribution Channel, 2018-2029 ($ Million)
Table 23 Europe Medical Marijuana Market Value, By Country, 2018-2029 ($ Million)
Table 24 Asia-Pacific Medical Marijuana Market Value, By Product Type, 2018-2029 ($ Million)
Table 25 Asia-Pacific Medical Marijuana Market Value, By Application, 2018-2029 ($ Million)
Table 26 Asia-Pacific Medical Marijuana Market Value, By Distribution Channel, 2018-2029 ($ Million)
Table 27 Asia-Pacific Medical Marijuana Market Value, By Country, 2018-2029 ($ Million)
Table 28 Middle East & Africa Medical Marijuana Market Value, By Product Type, 2018-2029 ($ Million)
Table 29 Middle East & Africa Medical Marijuana Market Value, By Application, 2018-2029 ($ Million)
Table 30 Middle East & Africa Medical Marijuana Market Value, By Distribution Channel, 2018-2029 ($ Million)
Table 31 GW Pharmaceuticals PLC: Overview
Table 32 GW Pharmaceuticals PLC: Product Portfolio
Table 33 GW Pharmaceuticals PLC: Key Developments
Table 34 MedReleaf Corporation: Overview
Table 35 MedReleaf Corporation: Product Portfolio
Table 36 MedReleaf Corporation: Key Developments
Table 37 Canopy Growth Corporation: Overview
Table 38 Canopy Growth Corporation: Product Portfolio
Table 39 Canopy Growth Corporation: Key Developments
Table 40 Aphria Incorporation: Overview
Table 41 Aphria Incorporation: Product Portfolio
Table 42 Aphria Incorporation: Key Developments
Table 43 Aurora Cannabis Inc: Overview
Table 44 Aurora Cannabis Inc: Product Portfolio
Table 45 Aurora Cannabis Inc: Key Developments
Table 46 Medical Marijuana, Inc.: Overview
Table 47 Medical Marijuana, Inc.: Product Portfolio
Table 48 Medical Marijuana, Inc.: Key Developments
Table 49 Green Relief Inc. Overview
Table 50 Green Relief Inc.: Product Portfolio
Table 51 Green Relief Inc.: Key Developments
Table 52 Chinese Academy Of Agricultural Sciences: Overview
Table 53 Chinese Academy Of Agricultural Sciences: Product Portfolio
Table 54 Chinese Academy Of Agricultural Sciences: Key Developments
Table 55 Chongqing Fujin Biology Medical Company: Overview
Table 56 Chongqing Fujin Biology Medical Company: Product Portfolio
Table 57 Chongqing Fujin Biology Medical Company: Key Developments
Table 58 Wanbang Medical Company: Overview
Table 59 Wanbang Medical Company: Product Portfolio
Table 60 Wanbang Medical Company: Key Developments
Table 01 Medical Marijuana Market Value, By Product Type, 2021, 2025 & 2029($ Million)
Table 02 Medical Marijuana Market Value, By Application, 2021, 2025 & 2029($ Million)
Table 03 Medical Marijuana Market Value, By Distribution Channel, 2021, 2025 & 2029($ Million)
Table 04 Medical Marijuana Market Value, By Product Type, 2021, 2025 & 2029($ Million)
Table 05 Medical Marijuana Market Value, By Product Type, 2018-2029 ($ Million)
Table 06 Medical Marijuana Market Value, By Application, 2021, 2025 & 2029($ Million)
Table 07 Medical Marijuana Market Value, By Application, 2018-2029 ($ Million)
Table 08 Medical Marijuana Market Value, By Distribution Channel, 2021, 2025 & 2029($ Million)
Table 09 Medical Marijuana Market Value, By Distribution Channel, 2018-2029 ($ Million)
Table 10 Medical Marijuana Market Value, By Region, 2021, 2025 & 2029($ Million)
Table 11 Medical Marijuana Market Value, By Region, 2018-2029 ($ Million)
Table 12 North America Medical Marijuana Market Value, By Product Type, 2018-2029 ($ Million)
Table 13 North America Medical Marijuana Market Value, By Application, 2018-2029 ($ Million)
Table 14 North America Medical Marijuana Market Value, By Distribution Channel, 2018-2029 ($ Million)
Table 15 North America Medical Marijuana Market Value, By Country, 2018-2029 ($ Million)
Table 16 South America Medical Marijuana Market Value, By Product Type, 2018-2029 ($ Million)
Table 17 South America Medical Marijuana Market Value, By Application, 2018-2029 ($ Million)
Table 18 South America Medical Marijuana Market Value, By Distribution Channel, 2018-2029 ($ Million)
Table 19 South America Medical Marijuana Market Value, By Country, 2018-2029 ($ Million)
Table 20 Europe Medical Marijuana Market Value, By Product Type, 2018-2029 ($ Million)
Table 21 Europe Medical Marijuana Market Value, By Application, 2018-2029 ($ Million)
Table 22 Europe Medical Marijuana Market Value, By Distribution Channel, 2018-2029 ($ Million)
Table 23 Europe Medical Marijuana Market Value, By Country, 2018-2029 ($ Million)
Table 24 Asia-Pacific Medical Marijuana Market Value, By Product Type, 2018-2029 ($ Million)
Table 25 Asia-Pacific Medical Marijuana Market Value, By Application, 2018-2029 ($ Million)
Table 26 Asia-Pacific Medical Marijuana Market Value, By Distribution Channel, 2018-2029 ($ Million)
Table 27 Asia-Pacific Medical Marijuana Market Value, By Country, 2018-2029 ($ Million)
Table 28 Middle East & Africa Medical Marijuana Market Value, By Product Type, 2018-2029 ($ Million)
Table 29 Middle East & Africa Medical Marijuana Market Value, By Application, 2018-2029 ($ Million)
Table 30 Middle East & Africa Medical Marijuana Market Value, By Distribution Channel, 2018-2029 ($ Million)
Table 31 GW Pharmaceuticals PLC: Overview
Table 32 GW Pharmaceuticals PLC: Product Portfolio
Table 33 GW Pharmaceuticals PLC: Key Developments
Table 34 MedReleaf Corporation: Overview
Table 35 MedReleaf Corporation: Product Portfolio
Table 36 MedReleaf Corporation: Key Developments
Table 37 Canopy Growth Corporation: Overview
Table 38 Canopy Growth Corporation: Product Portfolio
Table 39 Canopy Growth Corporation: Key Developments
Table 40 Aphria Incorporation: Overview
Table 41 Aphria Incorporation: Product Portfolio
Table 42 Aphria Incorporation: Key Developments
Table 43 Aurora Cannabis Inc: Overview
Table 44 Aurora Cannabis Inc: Product Portfolio
Table 45 Aurora Cannabis Inc: Key Developments
Table 46 Medical Marijuana, Inc.: Overview
Table 47 Medical Marijuana, Inc.: Product Portfolio
Table 48 Medical Marijuana, Inc.: Key Developments
Table 49 Green Relief Inc. Overview
Table 50 Green Relief Inc.: Product Portfolio
Table 51 Green Relief Inc.: Key Developments
Table 52 Chinese Academy Of Agricultural Sciences: Overview
Table 53 Chinese Academy Of Agricultural Sciences: Product Portfolio
Table 54 Chinese Academy Of Agricultural Sciences: Key Developments
Table 55 Chongqing Fujin Biology Medical Company: Overview
Table 56 Chongqing Fujin Biology Medical Company: Product Portfolio
Table 57 Chongqing Fujin Biology Medical Company: Key Developments
Table 58 Wanbang Medical Company: Overview
Table 59 Wanbang Medical Company: Product Portfolio
Table 60 Wanbang Medical Company: Key Developments
LIST OF FIGURES
Figure 01 Medical Marijuana Market Share, By Type, 2021 & 2029(%)
Figure 02 Medical Marijuana Market Share, By Application, 2021 & 2029(%)
Figure 03 Medical Marijuana Market Share, By Distribution Channel, 2021 & 2029(%)
Figure 04 Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 05 Medical Marijuana Market Y-o-Y Growth, By Type, 2021-2029 (%)
Figure 06 Extract Form: Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 07 Dried Form: Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 08 Medical Marijuana Market Y-o-Y Growth, By Applications, 2021-2029 (%)
Figure 09 Pain management: Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 10 Seizures: Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 11 Medical Marijuana Market Y-o-Y Growth, By Distribution Channel, 2021-2029 (%)
Figure 12 Retail Pharmacy : Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 13 E-Commerce : Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 14 Medical Marijuana Market Y-o-Y Growth, By Region, 2021-2029 (%)
Figure 15 North America Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 16 North America Medical Marijuana Market Share, By Product Type, 2021 & 2029(%)
Figure 17 North America Medical Marijuana Market Share, By Application, 2021 & 2029(%)
Figure18 North America Medical Marijuana Market Share, By Distribution Channel, 2021 & 2029(%)
Figure 19 North America Medical Marijuana Market Share, By Country, 2021 & 2029(%)
Figure 20 South America Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 21 South America Medical Marijuana Market Share, By Product Type, 2021 & 2029(%)
Figure 22 South America Medical Marijuana Market Share, By Application, 2021 & 2029(%)
Figure 23 South America Medical Marijuana Market Share, By Distribution Channel, 2021 & 2029(%)
Figure 24 South America Medical Marijuana Market Share, By Country, 2021 & 2029(%)
Figure 25 Europe Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 26 Europe Medical Marijuana Market Share, By Product Type, 2021 & 2029(%)
Figure 27 Europe Medical Marijuana Market Share, By Application, 2021 & 2029(%)
Figure 28 Europe Medical Marijuana Market Share, By Distribution Channel, 2021 & 2029(%)
Figure 29 Europe Medical Marijuana Market Share, By Country, 2021 & 2029(%)
Figure 30 Asia-Pacific Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 31 Asia-Pacific Medical Marijuana Market Share, By Product Type, 2021 & 2029(%)
Figure 32 Asia-Pacific Medical Marijuana Market Share, By Application, 2021 & 2029(%)
Figure 33 Asia-Pacific Medical Marijuana Market Share, By Distribution Channel, 2021 & 2029(%)
Figure 34 Asia-Pacific Medical Marijuana Market Share, By Country, 2021 & 2029(%)
Figure 35 Middle East & Africa Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 36 Middle East & Africa Medical Marijuana Market Share, By Product Type, 2021 & 2029(%)
Figure 37 Middle East & Africa Medical Marijuana Market Share, By Application, 2021 & 2029(%)
Figure 38 Middle East & Africa Medical Marijuana Market Share, By Distribution Channel, 2021 & 2029(%)
Figure 39 GW Pharmaceuticals PLC: Financials
Figure 40 MedReleaf Corporation: Financials
Figure 41 Canopy Growth Corporation: Financials
Figure 42 Aphria Incorporation: Financials
Figure 43 Aurora Cannabis Inc: Financials
Figure 44 Medical Marijuana, Inc.: Financials
Figure 45 Green Relief Inc. Financials
Figure 46 Chinese Academy Of Agricultural Sciences: Financials
Figure 47 Chongqing Fujin Biology Medical Company: Financials
Figure 48 Wanbang Medical Company: Financials
Figure 01 Medical Marijuana Market Share, By Type, 2021 & 2029(%)
Figure 02 Medical Marijuana Market Share, By Application, 2021 & 2029(%)
Figure 03 Medical Marijuana Market Share, By Distribution Channel, 2021 & 2029(%)
Figure 04 Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 05 Medical Marijuana Market Y-o-Y Growth, By Type, 2021-2029 (%)
Figure 06 Extract Form: Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 07 Dried Form: Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 08 Medical Marijuana Market Y-o-Y Growth, By Applications, 2021-2029 (%)
Figure 09 Pain management: Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 10 Seizures: Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 11 Medical Marijuana Market Y-o-Y Growth, By Distribution Channel, 2021-2029 (%)
Figure 12 Retail Pharmacy : Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 13 E-Commerce : Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 14 Medical Marijuana Market Y-o-Y Growth, By Region, 2021-2029 (%)
Figure 15 North America Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 16 North America Medical Marijuana Market Share, By Product Type, 2021 & 2029(%)
Figure 17 North America Medical Marijuana Market Share, By Application, 2021 & 2029(%)
Figure18 North America Medical Marijuana Market Share, By Distribution Channel, 2021 & 2029(%)
Figure 19 North America Medical Marijuana Market Share, By Country, 2021 & 2029(%)
Figure 20 South America Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 21 South America Medical Marijuana Market Share, By Product Type, 2021 & 2029(%)
Figure 22 South America Medical Marijuana Market Share, By Application, 2021 & 2029(%)
Figure 23 South America Medical Marijuana Market Share, By Distribution Channel, 2021 & 2029(%)
Figure 24 South America Medical Marijuana Market Share, By Country, 2021 & 2029(%)
Figure 25 Europe Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 26 Europe Medical Marijuana Market Share, By Product Type, 2021 & 2029(%)
Figure 27 Europe Medical Marijuana Market Share, By Application, 2021 & 2029(%)
Figure 28 Europe Medical Marijuana Market Share, By Distribution Channel, 2021 & 2029(%)
Figure 29 Europe Medical Marijuana Market Share, By Country, 2021 & 2029(%)
Figure 30 Asia-Pacific Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 31 Asia-Pacific Medical Marijuana Market Share, By Product Type, 2021 & 2029(%)
Figure 32 Asia-Pacific Medical Marijuana Market Share, By Application, 2021 & 2029(%)
Figure 33 Asia-Pacific Medical Marijuana Market Share, By Distribution Channel, 2021 & 2029(%)
Figure 34 Asia-Pacific Medical Marijuana Market Share, By Country, 2021 & 2029(%)
Figure 35 Middle East & Africa Medical Marijuana Market Value, 2018-2029 ($ Million)
Figure 36 Middle East & Africa Medical Marijuana Market Share, By Product Type, 2021 & 2029(%)
Figure 37 Middle East & Africa Medical Marijuana Market Share, By Application, 2021 & 2029(%)
Figure 38 Middle East & Africa Medical Marijuana Market Share, By Distribution Channel, 2021 & 2029(%)
Figure 39 GW Pharmaceuticals PLC: Financials
Figure 40 MedReleaf Corporation: Financials
Figure 41 Canopy Growth Corporation: Financials
Figure 42 Aphria Incorporation: Financials
Figure 43 Aurora Cannabis Inc: Financials
Figure 44 Medical Marijuana, Inc.: Financials
Figure 45 Green Relief Inc. Financials
Figure 46 Chinese Academy Of Agricultural Sciences: Financials
Figure 47 Chongqing Fujin Biology Medical Company: Financials
Figure 48 Wanbang Medical Company: Financials
